SILVER SPRING
Eylea HD dosing interval extended to 5 months
- Sponsor
- Regeneron Pharmaceuticals $REGN
- Drug
- Eylea HD · aflibercept
- Indication
- wet age-related macular degeneration and diabetic macular edema
FDA approved extended dosing intervals up to 5 months for Eylea HD (aflibercept) in wet age-related macular degeneration and diabetic macular edema.
What this means
Eylea HD is an eye injection that blocks abnormal blood vessel growth in wet macular degeneration and diabetic macular edema, helping prevent vision loss. The FDA now allows patients to receive the treatment every 5 months instead of more frequent doses after showing stable vision. This could mean fewer doctor visits for patients while maintaining the same vision protection, though individual response may vary.